Hosted on MSN5mon
GSK reports positive data for RSV shot in younger, at-risk adultsCurrently, Arexvy is approved in the US and EU for the prevention of RSV in people aged 60 and older and for people aged 50 to 59 who are at increased risk for the disease. More on GSK GSK: The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback